Investigation into Intellia Therapeutics by Faruqi & Faruqi, LLP

Faruqi & Faruqi, LLP, a prominent law firm specializing in securities litigation, is currently investigating potential claims against Intellia Therapeutics (NASDAQ: NTLA). The firm's Securities Litigation Partner, James (Josh) Wilson, is encouraging investors who experienced losses exceeding $50,000 in Intellia between July 30, 2024, and January 8, 2025, to reach out and explore their legal options.

If you believe you qualify, you can contact Josh Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310) to discuss your rights and possible actions to take.

The deadline to seek the role of lead plaintiff in a federal securities class action against Intellia is set for April 14, 2025. This is an important step for individuals who wish to recover losses related to the company's recent activities.

Faruqi & Faruqi is well regarded in the field, with operational offices in New York, Pennsylvania, California, and Georgia. Since its inception in 1995, the firm has successfully helped recover hundreds of millions of dollars for investors.

The investigation focuses on allegations that Intellia and its executives breached federal securities laws. The company is accused of making false and misleading statements regarding its Phase 1/2 study for the treatment of alpha-1 antitrypsin deficiency (AATD) that involves its drug candidate NTLA-3001. The allegations include claims of misrepresentation about the company's study timelines and a failure to disclose critical information that could impact the investment decisions of shareholders.

Particularly, the complaint suggests that Intellia misled investors about the demand for its viral-based editing approach, stating that there was significant interest in viral vector technologies. However, as noted in the emerging research community, non-viral methods have become the preferred option due to lower costs and more efficient results.

On January 9, 2025, Intellia announced its revised strategic focus, which included discontinuing the development of NTLA-3001 and reallocating resources towards other drug candidates such as NTLA-2002 and nex-z. This shift may also result in substantial workforce reductions of approximately 27% and an expected $8 million charge in restructuring costs in the first quarter of 2025. The announcement also included the retirement of Chief Scientific Officer Laura Sepp-Lorenzino.

Following this press release, Intellia's stock saw a significant decline, dropping $1.82 or 15.14%, closing at $10.20 per share on January 10, 2025.

Investors should be aware that the lead plaintiff is typically the person with the largest financial stake in the case who also fulfills the requirement of being able to adequately represent the class. Every member of the potential class has the right to apply to be the lead plaintiff through their chosen legal counsel.

Faruqi & Faruqi encourages anyone with insights or information about Intellia Therapeutics' practices to come forward. This includes whistleblowers, former employees, shareholders, and other relevant parties.

For further details regarding the Intellia Therapeutics class action, please explore the firm’s website or contact Josh Wilson.

Stay connected for updates on LinkedIn, Twitter, or related social media platforms.

Note that this article is part of attorney advertising. Faruqi & Faruqi, LLP is the entity responsible for this announcement, and prior settlement amounts do not guarantee similar results in future cases.

Intellia, investment, lawsuit